A Randomized Trial of Nelfinavir and Abacavir in Combination with Efavirenz and Adefovir Dipivoxil in HIV-1-Infected Persons with Virological Failure Receiving Indinavir

Palella F.J. Jr. , Delaney K.M. , Moorman A.C. , Loveless M.O. , Fuhrer J. , Satten G.A. , Aschman D.J. , & Holmberg S.D. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. New England Journal of Medicine 1998; 338(13): 853–860.

Yeni P.G. , Hammer S.M. , Carpenter C.C. , Cooper D.A. , Fischl M.A. , Gatell J.M. , Gazzard B.G. , Hirsch M.S. , Jacobsen D.M. , Katzenstein D.A. , Montaner J.S. , Richman D.D. , Saag M.S. , Schechter M. , Schooley R.T. , Thompson M.A. , Vella S. , & Volberding P.A. Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel. Journal of the American Medical Association 2002; 288(2): 222–235.

DHHS/Kaiser. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Available at: http://www.hivatis.org.

Gulick R.M. , Mellors J.W. , Havlir D. , Eron J.J. , Meibohm A. , Condra J.H. , Valentine F.T. , McMahon D. , Gonzalez C. , Jonas L. , Emini E.A. , Chodakewitz J.A. , Isaacs R. , & Richman D.D. 3-year suppression of HIV viremia with indinavir, zidovudine, and lamivudine. Annals of Internal Medicine 2000; 133(1): 35–39.

Baxter J.D. , Mayers D.L. , Wentworth D.N. , Neaton J.D. , Hoover M.L. , Winters M.A. , Mannheimer S.B. , Thompson M.A. , Abrams D.I. , Brizz B.J. , Ioannidis J.P. , & Merigan T.C. A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. CPCRA 046 Study Team for the Terry Beirn Community Programs for Clinical Research on AIDS. AIDS 2000; 14(9): F83–F93.

DeGruttola V. , Dix L. , D'Aquila R. , Holder D. , Phillips A. , Ait-Khaled M. , Baxter J. , Clevenbergh P. , Hammer S. , Harrigan R. , Katzenstein D. , Lanier R. , Miller M. , Para M. , Yerly S. , Zolopa A. , Murray J. , Patick A. , Miller V. , Castillo S. , Pedneault L. , & Mellors J. The relation between baseline HIV drug resistance and response to antiretroviral therapy: re-analysis of retrospective and prospective studies using a standardized data analysis plan. Antiviral Therapy 2000; 5(1): 41–48.

Cohen C.J. , Hunt S. , Sension M. , Farthing C. , Conant M. , Jacobson S. , Nadler J. , Verbiest W. , Hertogs K. , Ames M. , Rinehart A.R. , & Graham N.M. A randomized trial assessing the impact of phenotypic resistance testing on antiretroviral therapy. AIDS 2002; 16(4): 579–588.

Hammer S.M. , Vaida F. , Bennett K.K. , Holohan M.K. , Sheiner L. , Eron J.J. , Wheat L.J. , Mitsuyasu R.T. , Gulick R.M. , Valentine F.T. , Aberg J.A. , Rogers M.D. , Karol C.N. , Saah A.J. , Lewis R.H. , Bessen L.J. , Brosgart C. , DeGruttola V. , & Mellors J.W. Dual vs single protease inhibitor therapy following antiretroviral treatment failure: a randomized trial. Journal of the American Medical Association 2002; 288(2): 169–180.

Clevenbergh P. , Durant J. , Halfon P. , del Giudice P. , Mondain V. , Montagne N. , Schapiro J.M. , Boucher C.A. , & Dellamonica P. Persisting long-term benefit of genotype-guided treatment for HIV-infected patients failing HAART. The Viradapt Study: week 48 follow-up. Antiviral Therapy 2000; 5(1): 65–70.

Durant J. , Clevenbergh P. , Halfon P. , Delgiudice P. , Porsin S. , Simonet P. , Montagne N. , Boucher C.A. , Schapiro J.M. , & Dellamonica P. Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomised controlled trial. Lancet 1999; 353(9171): 2195–2199.

Haubrich R. , & Demeter L. International perspectives on antiretroviral resistance. Clinical utility of resistance testing: retrospective and prospective data supporting use and current recommendations. Journal of Acquired Immune Deficiency Syndromes 2001; 26(Suppl. 1): S51–S59.

Hammer S.M. , Squires K.E. , Hughes M.D. , Grimes J.M. , Demeter L.M. , Currier J.S. , Eron J.J. Jr. , Feinberg J.E. , Balfour H.H. Jr. , Deyton L.R. , Chodakewitz J.A. , & Fischl M.A. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. New England Journal of Medicine 1997; 337(11): 725–733.

Hertogs K. , de Bethune M.P. , Miller V. , Ivens T. , Schel P. , Van Cauwenberge A. , Van Den Eynde C. , Van Gerwen V. , Azijn H. , Van Houtte M. , Peeters F. , Staszewski S. , Conant M. , Bloor S. , Kemp S. , Larder B. , & Pauwels R. A rapid method for simultaneous detection of phenotypic resistance to inhibitors of protease and reverse transcriptase in recombinant human immunodeficiency virus type 1 isolates from patients treated with antiretroviral drugs. Antimicrobial Agents & Chemotherapy 1998; 42(2): 269–276.

Hertogs K. , Bloor S. , De Vroey V. , van Den Eynde C. , Dehertogh P. , van Cauwenberge A. , Sturmer M. , Alcorn T. , Wegner S. , van Houtte M. , Miller V. , & Larder B.A. A novel human immunodeficiency virus type 1 reverse transcriptase mutational pattern confers phenotypic lamivudine resistance in the absence of mutation 184V. Antimicrobial Agents & Chemotherapy 2000; 44(3): 568–573.

Harrigan P.R. , Hertogs K. , Verbiest W. , Pauwels R. , Larder B. , Kemp S. , Bloor S. , Yip B. , Hogg R. , Alexander C. , & Montaner J.S. Baseline HIV drug resistance profile predicts response to ritonavir-saquinavir protease inhibitor therapy in a community setting. AIDS 1999; 13(14): 1863–1871.

Tebas P. , Patick A.K. , Kane E.M. , Klebert M.K. , Simpson J.H. , Erice A. , Powderly W.G. , & Henry K. Virologic responses to a ritonavir-saquinavir-containing regimen in patients who had previously failed nelfinavir. AIDS 1999; 13(2): F23–F28.

Walter H. , Schmidt B. , Werwein M. , Schwingel E. , & Korn K. Prediction of abacavir resistance from genotypic data: impact of zidovudine and lamivudine resistance in vitro and in vivo. Antimicrobial Agents & Chemotherapy 2002; 46(1): 89–94.

Gulick R.M. , Hu X.J. , Fiscus S.A. , Fletcher C.V. , Haubrich R. , Cheng H. , Acosta E. , Lagakos S.W. , Swanstrom R. , Freimuth W. , Snyder S. , Mills C. , Fischl M. , Pettinelli C. , & Katzenstein D. Randomized study of saquinavir with ritonavir or nelfinavir together with delavirdine, adefovir, or both in human immunodeficiency virus-infected adults with virologic failure on indinavir: AIDS Clinical Trials Group Study 359. Journal of Infectious Diseases 2000; 182(5): 1375–1384.

Benson C.A. , Deeks S.G. , Brun S.C. , Gulick R.M. , Eron J.J. , Kessler H.A. , Murphy R.L. , Hicks C. , King M. , Wheeler D. , Feinberg J. , Stryker R. , Sax P.E. , Riddler S. , Thompson M. , Real K. , Hsu A. , Kempf D. , Japour A.J. , & Sun E. Safety and antiviral activity at 48 weeks of lopinavir/ritonavir plus nevirapine and 2 nucleoside reverse-transcriptase inhibitors in human immunodeficiency virus type 1-infected protease inhibitor-experienced patients. Journal of Infectious Diseases 2002; 185(5): 599–607.

Falloon J. , Ait-Khaled M. , Thomas D.A. , Brosgart C.L. , Eron J.J. Jr , Feinberg J. , Flanigan T.P. , Hammer S.M. , Kraus P.W. , Murphy R. , Torres R. , & Masur H. HIV-1 genotype and phenotype correlate with virological response to abacavir, amprenavir and efavirenz in treatment-experienced patients. AIDS 2002; 16(3): 387–396.

Hirsch M.S. , Brun-Vezinet F. , D'Aquila R.T. , Hammer S.M. , Johnson V.A. , Kuritzkes D.R. , Loveday C. , Mellors J.W. , Clotet B. , Conway B. , Demeter L.M. , Vella S. , Jacobsen D.M. , & Richman D.D. Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society-USA Panel. Journal of the American Medical Association 2000; 283(18): 2417–2426.

Montaner J.S. , Harrigan P.R. , Jahnke N. , Raboud J. , Castillo E. , Hogg R.S. , Yip B. , Harris M. , Montessori V. , & O'Shaughnessy M.V. Multiple drug rescue therapy for HIV-infected individuals with prior virologic failure to multiple regimens. AIDS 2001; 15(1): 61–69.

Miller V. , Sabin C. , Hertogs K. , Bloor S. , Martinez-Picado J. , D'Aquila R. , Larder B. , Lutz T. , Gute P. , Weidmann E. , Rabenau H. , Phillips A. , & Staszewski S. Virological and immunological effects of treatment interruptions in HIV-1 infected patients with treatment failure. AIDS 2000; 14(18): 2857–2867.

Deeks S.G. , Wrin T. , Liegler T. , Hoh R. , Hayden M. , Barbour J.D. , Hellmann N.S. , Petropoulos C.J. , McCune J.M. , Hellerstein M.K. , & Grant R.M. Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia. New England Journal of Medicine 2001; 344(7): 472–480.

Rutschmann O.T. , Vernazza P.L. , Bucher H.C. , Opravil M. , Ledergerber B. , Telenti A. , Malinverni R. , Bernasconi E. , Fagard C. , Leduc D. , Perrin L. , & Hirschel B. Long-term hydroxyurea in combination with didanosine and stavudine for the treatment of HIV-1 infection. Swiss HIV Cohort Study. AIDS 2000; 14(14): 2145–2151.

Margolis D.M. , Kewn S. , Coull J.J. , Ylisastigui L. , Turner D. , Wise H. , Hossain M.M. , Lanier E.R. , Shaw L.M. , & Back D. The addition of mycophenolate mofetil to antiretroviral therapy including abacavir is associated with depletion of intracellular deoxyguanosine triphosphate and a decrease in plasma HIV-1 RNA. Journal of Acquired Immune Deficiency Syndromes 2002; 31(1): 45–49.

Lalezari J.P. , Henry K. , O'Hearn M. , Montaner J.S.G. , Piliero P.J. , Trottier B. , Walmsley S. , Cohen C. , Kuritzkes D.R. , Eron J.J. Jr. , Chung J. , DeMasi R. , Donatacci L. , Drobnes C. , Delehanty J. , & Salgo M. for the TORO 1 Study Group. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. New England Journal of Medicine 2003; 348: 2175–2185.

Lazzarin A. , Clotet B. , Cooper D. , Reynes J. , Arasteh K. , Nelson M. , Katlama C. , Stellbrink H.J. , Delfraissy J.F. , Lange J. , Huson L. , DeMasi R. , Wat C. , Delehanty J. , Drobnes C. , Salgo M. ; TORO 2 Study Group. Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. New England Journal of Medicine 2003; 348: 2186–2195.